

Eurobio Scientific partners with Dr. Nino Guy Cassuto for the development of a new PCR test for male fertility

- Accelerating the extension of the proprietary portfolio of routine tests in molecular biology.
- First test for accurate and rapid quantification of genetic markers of spermatozoa linked to infertility.
- Molecular biology test deployable routinely in public and private biology laboratories, refining the diagnosis of male infertility in addition to sperm parameters.

Paris, April 26, 2022 – 5:45 pm

Eurobio Scientific (FR0013240934, ALERS), a leading French group in specialty in vitro medical diagnostics, announces today that it entered into an exclusive worldwide license agreement with Doctor Nino Guy Cassuto for the development, manufacturing and marketing of a new test in relation with his patents related to a new method for selecting spermatozoa, in particular for medically assisted reproduction (ART).

Development of a new proprietary test

In this context, Eurobio Scientific, with its know-how in molecular biology, will undertake the development, validation and marketing of a test for the quantification by qRT-PCR¹ of genetic markers identified by Dr. Cassuto for the screening of patients at risk of infertility. This test, which will complement routinely measured sperm parameters, will give a more precise approach in the exploration of male fertility.

This new molecular biology test, designed and developed by Eurobio Scientific R&D, will be produced in-house at its premises in Les Ulis, France, and should be available during the second half of 2022 in its RUO version for hospital and private laboratories, both in France and internationally.

A new strategy for the management of male infertility

The causes of male infertility are diverse and can have their origin in a mechanical or hormonal dysfunction or in connection with sperm abnormalities. These can affect the number, motility and shape of spermatozoa. Dr. Cassuto did a lot of research and wrote numerous publications within this medical field, through his specialized practice in the Drouot laboratory in Paris, leading to significant advances in the understanding of the link between the quality of sperm DNA and male infertility. He thus highlighted the potential role of several genes which lack of expression is correlated with alterations in the morphology of spermatozoa, and which can impact early embryonic development in ART, in partially fertile or even infertile patients.²

¹ The "Polymerase Chain Reaction" (PCR) is a method based on the selective multiplication of target DNA sequences, which makes it possible to detect specific DNA sequences present in a product. qRT-PCR is a real-time quantitative PCR.

² Cassuto, Piquemal, Boitrelle, & Al "Molecular Profiling of Spermatozoa Reveals Correlations between Morphology and Gene Expression: A Novel Biomarker Panel for Male Infertility", BioMed Research International, September 2021.

A test allowing the quantification of the expression of these markers would facilitate the selection of spermatozoa used in the context of in vitro fertilization (IVF) by injection of the spermatozoa into the oocyte (ICSI), therefore reducing the risk of failures. It would be part of a new strategy for better care of applicants for ART, while promoting cost control.

A growing market

In general, the global market for assisted reproductive technologies (ART) is growing every year at the global level. With an average growth of around 10% per year, it is expected to reach \$45 billion in 2025³, with just over 11% growth for IVF⁴.

Currently, approximately 62,000 IVF and 50,000 inseminations are performed each year in France. In addition to these ART acts, there are a number of preparatory medical acts which result in the performance of around 370,000 sperm parameters assessments per year⁵, which would translate, on a European level, into an overall potential of around 2 million analyzes per year that could be supplemented by the added value provided by a new PCR test.

The development of this new test by Eurobio Scientific is therefore part of the standardization of practices related to assisted reproduction, standardization made necessary by the continuous growth in the number of medical acts.

Next financial meeting

Annual shareholders' meeting : June 13, 2022

Disclaimer

This press release contains elements that are not historical facts including, without limitation, certain statements about future expectations and other forward-looking statements. Such statements are based on management's current views and assumptions and involve known and unknown risks and uncertainties that could cause actual results, profitability or events to differ materially from those anticipated. In addition, Eurobio Scientific, its shareholders, and its affiliates, directors, officers, advisors and employees have not verified the accuracy of, and make no representations or warranties in relation to, statistical data or predictions contained in this press release that were taken or derived from third party sources or industry publications. Such statistical data and predictions are used in this press release for information purposes only. Finally, this press release may be drafted in the French and English languages. If both versions are interpreted differently, the French language version shall prevail.

About Eurobio Scientific

Eurobio Scientific is a key player in the field of specialty in vitro diagnostics. It is involved from research to manufacturing and commercialization of diagnostic tests in the fields of transplantation, immunology and infectious diseases, and sells instruments and products for research laboratories, including biotechnology and pharmaceutical companies. Through many partnerships and a strong presence in hospitals, Eurobio Scientific has established its own distribution network and a portfolio of proprietary products in the molecular biology field. The Group has approximately 165 employees and three production units based in the Paris region, in Germany and in the United States, and several affiliates based in Dorking UK, Sissach Switzerland, Bünde Germany and Utrecht in The Netherlands.

For more information, please visit : www.eurobio-scientific.com

The company is publicly listed on the Euronext Growth market in Paris

Euronext Growth BPI Innovation, PEA-PME 150 and Next Biotech indices, Euronext European Rising Tech label.

Symbol: ALERS - ISIN Code: FR0013240934 - Reuters: ALERS.PA - Bloomberg: ALERS:FP

Contacts

Group Eurobio Scientific

Denis Fortier, General Manager
Hervé Duchesne de Lamotte, General Manager
Tel. +33(0) 1 69 79 64 80

Calyptus

Mathieu Calleux / Maisie Mouret
Investors relations
Tel. +33(1) 53 65 68 68
eurobio-scientific@calyptus.net

³ Source : Grand View Research 2018

⁴ Source : Frost & Sullivan 2019

⁵ Source : AMELI 2022

